Clinical Trial Update: A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase II study evaluating Epstein-Barr virus–specific immunotherapy for nasopharyngeal carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Epstein-Barr Virus-Specific Immunotherapy

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-06-28